BeiGene Doses First Patient for Trial in China

BeiGene (NASDAQ:BGNE) announced the first patient dosing for a cancer treatment clinical trial in China.

As quoted in the press release:

The first patient was dosed in a pivotal clinical trial of BGB-A317, an investigational anti-PD-1 antibody, in Chinese patients with relapsed or refractory classical Hodgkin lymphoma (cHL).

“We are dedicated to developing BGB-A317 broadly in China, where no immune checkpoint inhibitors are currently approved despite the considerable unmet need in patients with the country’s most prevalent cancers. In addition to a registration program in China, we also plan to initiate studies to enable regulatory approval of BGB-A317 in multiple geographies outside of China,” commented John V. Oyler, Founder, Chief Executive Officer, and Chairman.

“BGB-A317 has been administered to over 400 patients globally, and we have presented clinical data at international conferences demonstrating that this agent is well-tolerated with anti-tumor activity observed in multiple tumor types. We are pursuing the approval of our PD-1 antibody for patients with relapsed or refractory Hodgkin lymphoma in China because of the urgent unmet medical need and significant activity observed with this class of agents in this setting,” commented Jane E. Huang, M.D., Chief Medical Officer, Hematology.

Click here to read the full press release.

Get the Latest Biotech Investing Stock Information

Get the latest information about companies associated with Biotech Investing delivered directly to your inbox.


By selecting company or companies above, you are giving consent to receive email from those companies. And remember you can unsubscribe at any time.


Leave a Reply